AI-Generated Summary

The pharmaceutical industry in Bulgaria warns that the government's mandatory rebate policy is jeopardizing patients' access to innovative therapies and threatening the long-term sustainability of the healthcare system. Industry experts argue these rebates, which can exceed actual medicine sales, effectively transfer the state's healthcare deficit onto companies. This situation risks Bulgaria falling behind other EU nations in healthcare innovation and access, according to the Association of Research-based Pharmaceutical Manufacturers in Bulgaria.

In a nutshell

This situation highlights the delicate balance between national healthcare budgeting and fostering a viable market for pharmaceutical innovation. For pharmaceutical executives and regulatory specialists, it underscores the persistent challenges of market access and pricing negotiations in emerging EU markets.

Source: Euractiv